Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care

About this episode

Dr. Raphael Schneider discusses the impact of multiplex proteomic biomarker panels on understanding and monitoring multiple sclerosis.

Guest: Raphael Schneider, MD, PhD, FRCPC, CIP Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from Dr. Raphael Schneider as he explores how these tools could inform prognosis, risk stratification, and clinical trial design, which he spoke about at the 2026 ACTRIMS Forum. Dr. Schneider is a neurologist and researcher at the BARLO MS Centre at St. Michael’s Hospital as well as an Assistant Professor and the Elizabeth S. Barford Early Career Professor in Multiple Sclerosis in the Department of Medicine at the University of Toronto.

People in this episode

Guests: Raphael Schneider, MD, PhD, FRCPC, CIP, Raphael Schneider

Topics covered

• multiplex proteomic biomarkers
• multiple sclerosis
• precision care
• prognosis
• risk stratification
• clinical trial design

Keywords

• multiplex proteomic biomarkers
• multiple sclerosis
• precision care
• prognosis
• risk stratification
• clinical trials

Mentioned in this episode

Organizations: BARLO MS Centre, St. Michael’s Hospital, University of Toronto

More episodes of NeuroFrontiers

• Navigating Stem Cell Therapy Conversations in MS · June 8, 2026 · 5 min
• Cognitive Screening in MS: Practical Strategies and Modern Approaches · May 28, 2026 · 4 min
• Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role · May 14, 2026 · 15 min
• Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols · May 14, 2026 · 14 min
• Understanding Variability in Myasthenia Gravis · May 1, 2026 · 4 min
• Examining the Global Genetic Prevalence of TK2d · April 30, 2026 · 14 min